Alexander Darwin Vuong Pham, MD
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 30
- 7 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
30 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Pham’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
30 of 30 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A112936 · Current
Licensed to practise in California · since 2010 · expires 2027-08-31 · Drexel University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$152,935
Medicare paid this office $152,935 for 437 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 253 | $93,478 | $132 |
| Return visit (30+ min) | 192 | $22,679 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $11,620 | $106 |
| New patient visit (60+ min) | 76 | $11,523 | $152 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 303 | $9,845 | $15 |
See all 7 services
| Long return visit (40+ min) | 253 | $93,478 | $132 |
| Return visit (30+ min) | 192 | $22,679 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $11,620 | $106 |
| New patient visit (60+ min) | 76 | $11,523 | $152 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 303 | $9,845 | $15 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,705 | $142 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,579 | $105 |
Who their Medicare patients are
437 Original Medicare patients in 2024. Average age 77 · Under 65 4% · 85 and older 19% · Women 61% · Also on Medicaid 16% · Health risk score 1.82. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Cancer 41% · Coronary heart disease 33% · Diabetes 32% · Chronic kidney disease 32% · Atrial fibrillation 22% · Heart failure 19% · Depression 19% · COPD 15% · Stroke 11% · Dementia 8%.
The office billed $491,640, Medicare allowed $205,601 and paid $152,935; for 1,864 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 437 | 1,864 | 77 | 1.82 | $491,640 | $152,935 |
| 2023 | 435 | 1,298 | 77 | 1.93 | $378,913 | $144,307 |
| 2022 | 428 | 1,305 | 77 | 1.74 | $511,828 | $139,749 |
| 2021 | 445 | 1,357 | 77 | 1.99 | $553,041 | $146,022 |
| 2020 | 384 | 1,273 | 77 | 2.07 | $371,725 | $105,413 |
| 2019 | 384 | 1,588 | 76 | 2.09 | $250,313 | $126,978 |
| 2018 | 380 | 16,166 | 77 | 1.97 | $1,219,998 | $305,524 |
| 2017 | 347 | 26,783 | 77 | 2.08 | $2,562,631 | $538,532 |
| 2016 | 285 | 18,480 | 76 | 2.08 | $992,107 | $299,297 |
| 2015 | 85 | 1,244 | 77 | 2.05 | $84,472 | $27,868 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Long return visit (40+ min) | 231 | $82,838 | $123 |
| Return visit (30+ min) | 201 | $25,352 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $16,614 | $107 |
| New patient visit (60+ min) | 78 | $12,078 | $155 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $5,252 | $107 |
2022: 5 services
| Long return visit (40+ min) | 198 | $78,808 | $121 |
| Return visit (30+ min) | 215 | $27,870 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 59 | $16,971 | $93 |
| New patient visit (60+ min) | 81 | $12,688 | $157 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,855 | $178 |
2021: 6 services
| Long return visit (40+ min) | 248 | $84,106 | $123 |
| Return visit (30+ min) | 226 | $25,670 | $75 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $19,975 | $97 |
| New patient visit (60+ min) | 70 | $11,967 | $171 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,035 | $185 |
| Short return visit (20+ min) | 17 | $897 | $43 |
2020: 7 services
| Long return visit (40+ min) | 82 | $39,518 | $99 |
| Return visit (30+ min) | 246 | $31,745 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $12,488 | $97 |
| New patient visit (60+ min) | 65 | $9,991 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 53 | $7,679 | $67 |
| Short return visit (20+ min) | 50 | $1,878 | $32 |
| Telehealth originating site facility fee | 14 | $298 | $21 |
2019: 7 services
| Long return visit (40+ min) | 121 | $45,529 | $97 |
| Return visit (30+ min) | 255 | $37,639 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $15,281 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $9,505 | $66 |
| New patient visit (60+ min) | 66 | $9,328 | $141 |
| Short return visit (20+ min) | 103 | $5,290 | $41 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,405 | $184 |
2018: 8 services
| Return visit (30+ min) | 282 | $70,270 | $69 |
| Long return visit (40+ min) | 63 | $16,638 | $101 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 71 | $13,790 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $9,353 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $9,262 | $175 |
| New patient visit (60+ min) | 62 | $8,932 | $144 |
| Short return visit (20+ min) | 35 | $1,800 | $44 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 30 | $846 | $9 |
2017: 14 services
| Return visit (30+ min) | 247 | $74,673 | $88 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $16,520 | $142 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 73 | $12,503 | $65 |
| New patient visit (60+ min) | 67 | $12,358 | $182 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $7,977 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $6,915 | $93 |
| Long return visit (40+ min) | 25 | $3,807 | $127 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 11 | $3,765 | $31 |
| Short return visit (20+ min) | 38 | $3,273 | $64 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 56 | $2,926 | $10 |
| Injection of drug or substance under skin or into muscle | 13 | $2,609 | $26 |
| Injection of additional new drug or substance into vein | 12 | $1,445 | $23 |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $76 | None |
| Insertion of needle into vein for collection of blood sample | 13 | $65 | $3 |
2016: 10 services
| Return visit (30+ min) | 171 | $45,621 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $9,882 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 72 | $9,790 | $64 |
| New patient visit (60+ min) | 36 | $6,429 | $179 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $4,434 | $92 |
| Long return visit (40+ min) | 21 | $3,770 | $135 |
| Short return visit (20+ min) | 30 | $3,569 | $69 |
| New patient visit (45+ min) | 24 | $3,355 | $140 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 58 | $2,190 | $10 |
| Insertion of needle into vein for collection of blood sample | 35 | $185 | $3 |
2015: 3 services
| Short return visit (20+ min) | 34 | $2,407 | $67 |
| Return visit (30+ min) | 20 | $2,121 | $101 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 13 | $166 | $10 |
Medicaid work
$972 in 2024
Medicaid paid $972 for 27 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 27 | $972 |
| 2024 | 27 | 1 | 13 | $972 |
| 2023 | 211 | 1 | 22 | $7,059 |
| 2022 | 212 | 1 | 19 | $7,069 |
| 2021 | 111 | 2 | 18 | $3,779 |
| 2018 | 15 | 1 | 12 | $359 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 211 | $7,059 |
2022
| Long return visit (40+ min) | 212 | $7,069 |
2021
| Long return visit (40+ min) | 95 | $3,346 |
| Return visit (30+ min) | 16 | $434 |
2018
| Return visit (30+ min) | 15 | $359 |
Drugs they prescribed that Part D paid
$876,287
Pharmacies billed $876,287 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
263 generic and fewer than 11 brand-name prescriptions · $876,287 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ibrance | 14 | $216,241 | $15,446 |
| Eliquis | 27 | $21,645 | $802 |
| Abiraterone Acetate | 20 | $7,087 | $354 |
| Anastrozole | 50 | $1,242 | $25 |
| Dexamethasone | 25 | $415 | $17 |
See all 9 drugs
| Ibrance | 14 | $216,241 | $15,446 |
| Eliquis | 27 | $21,645 | $802 |
| Abiraterone Acetate | 20 | $7,087 | $354 |
| Anastrozole | 50 | $1,242 | $25 |
| Dexamethasone | 25 | $415 | $17 |
| Letrozole | 11 | $299 | $27 |
| Hydroxyurea | 19 | $269 | $14 |
| Lidocaine-Prilocaine | 12 | $147 | $12 |
| Prednisone | 25 | $110 | $4 |
Year by year
| 2024 | 345 | 92 | None | None | $876,287 |
| 2023 | 296 | 92 | None | 21% | $814,641 |
| 2022 | 367 | 80 | 3% (12) | 38% | $1,607,577 |
| 2021 | 449 | 106 | None | 39% | $2,261,030 |
| 2020 | 476 | 110 | None | 34% | $1,756,812 |
| 2019 | 818 | 140 | 1% (11) | None | $1,985,573 |
| 2018 | 910 | 146 | 4% (32) | 23% | $1,706,395 |
| 2017 | 815 | 134 | 6% (49) | 19% | $1,006,903 |
| 2016 | 404 | 87 | 4% (17) | None | $336,519 |
| 2015 | 66 | 25 | None | 20% | $80,670 |
| 2014 | 47 | 17 | None | 23% | $44,685 |
| 2013 | 45 | 20 | 29% (13) | None | $29,755 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Inlyta | 13 | $285,231 | $21,941 |
| Eliquis | 15 | $9,983 | $666 |
| Abiraterone Acetate | 22 | $8,280 | $376 |
| Anastrozole | 22 | $754 | $34 |
| Ondansetron | 15 | $589 | $39 |
| Hydroxyurea | 13 | $423 | $33 |
| Dexamethasone | 12 | $297 | $25 |
| Prednisone | 18 | $209 | $12 |
| Omeprazole | 12 | $124 | $10 |
2022: 12 drugs
| Revlimid | 23 | $516,044 | $22,437 |
| Inlyta | 12 | $239,977 | $19,998 |
| Tagrisso | 12 | $180,599 | $15,050 |
| Lynparza | 12 | $110,015 | $9,168 |
| Eliquis | 23 | $14,068 | $612 |
| Enoxaparin | 11 | $4,738 | $431 |
| Anastrozole | 24 | $730 | $30 |
| Dexamethasone | 15 | $430 | $29 |
| Gabapentin | 15 | $430 | $29 |
| Hydroxyurea | 11 | $410 | $37 |
| Ondansetron | 15 | $310 | $21 |
| Prochlorperazine Maleate | 12 | $155 | $13 |
2021: 12 drugs
| Revlimid | 50 | $1,127,175 | $22,543 |
| Xtandi | 11 | $144,485 | $13,135 |
| Abiraterone Acetate | 17 | $37,762 | $2,221 |
| Eliquis | 27 | $14,417 | $534 |
| Xarelto | 20 | $12,846 | $642 |
| Hydroxyurea | 17 | $1,394 | $82 |
| Anastrozole | 31 | $942 | $30 |
| Dexamethasone | 22 | $748 | $34 |
| Ondansetron | 19 | $266 | $14 |
| Gabapentin | 18 | $259 | $14 |
| Prochlorperazine Maleate | 15 | $201 | $13 |
| Prednisone | 12 | $119 | $10 |
2020: 13 drugs
| Revlimid | 48 | $949,985 | $19,791 |
| Tagrisso | 12 | $189,666 | $15,806 |
| Xarelto | 22 | $11,097 | $504 |
| Eliquis | 17 | $7,911 | $465 |
| Hydroxyurea | 21 | $1,413 | $67 |
| Anastrozole | 44 | $1,111 | $25 |
| Dexamethasone | 36 | $908 | $25 |
| Tamoxifen Citrate | 17 | $402 | $24 |
| Prochlorperazine Maleate | 16 | $309 | $19 |
| Prednisone | 22 | $236 | $11 |
| Ondansetron | 14 | $207 | $15 |
| Acyclovir | 20 | $177 | $9 |
| Famotidine | 14 | $165 | $12 |
2019: 20 drugs
| Revlimid | 29 | $618,143 | $21,315 |
| Tagrisso | 30 | $445,798 | $14,860 |
| Imbruvica | 25 | $313,320 | $12,533 |
| Ibrance | 12 | $139,581 | $11,632 |
| Xarelto | 17 | $14,068 | $828 |
| Eliquis | 23 | $13,271 | $577 |
| Anastrozole | 109 | $2,905 | $27 |
| Hydroxyurea | 45 | $2,320 | $52 |
| Tamoxifen Citrate | 45 | $1,604 | $36 |
| Mirtazapine | 25 | $1,344 | $54 |
| Dexamethasone | 56 | $1,122 | $20 |
| Gabapentin | 18 | $698 | $39 |
| Letrozole | 30 | $690 | $23 |
| Acyclovir | 38 | $543 | $14 |
| Ondansetron | 32 | $498 | $16 |
| Diphenoxylate-Atropine | 11 | $217 | $20 |
| Prednisone | 16 | $149 | $9 |
| Omeprazole | 17 | $114 | $7 |
| Prochlorperazine Maleate | 13 | $113 | $9 |
| Lorazepam | 12 | $31 | $3 |
2018: 23 drugs
| Revlimid | 38 | $635,832 | $16,732 |
| Tagrisso | 20 | $298,360 | $14,918 |
| Imbruvica | 19 | $211,294 | $11,121 |
| Gleevec | 13 | $126,986 | $9,768 |
| Xarelto | 26 | $13,090 | $503 |
| Eliquis | 20 | $8,732 | $437 |
| Exemestane | 18 | $6,601 | $367 |
| Anastrozole | 137 | $2,750 | $20 |
| Hydroxyurea | 52 | $2,439 | $47 |
| Mirtazapine | 37 | $2,074 | $56 |
| Tamoxifen Citrate | 46 | $1,897 | $41 |
| Dexamethasone | 38 | $592 | $16 |
| Gabapentin | 23 | $576 | $25 |
| Hydrocodone-Acetaminophen | 19 | $515 | $27 |
| Letrozole | 29 | $474 | $16 |
| Acyclovir | 34 | $426 | $13 |
| Ondansetron | 30 | $425 | $14 |
| Oxycodone-Acetaminophen | 11 | $347 | $32 |
| Prochlorperazine Maleate | 20 | $195 | $10 |
| Omeprazole | 20 | $160 | $8 |
| Lorazepam | 26 | $104 | $4 |
| Warfarin | 12 | $104 | $9 |
| Sulfamethoxazole-Trimethoprim | 16 | $71 | $4 |
2017: 19 drugs
| Revlimid | 34 | $436,601 | $12,841 |
| Tarceva | 25 | $190,908 | $7,636 |
| Imbruvica | 18 | $167,003 | $9,278 |
| Gleevec | 12 | $117,825 | $9,819 |
| Xarelto | 23 | $9,139 | $397 |
| Anastrozole | 156 | $2,437 | $16 |
| Hydroxyurea | 32 | $1,591 | $50 |
| Tamoxifen Citrate | 30 | $1,049 | $35 |
| Hydrocodone-Acetaminophen | 26 | $858 | $33 |
| Hydrocortisone | 20 | $529 | $26 |
| Acyclovir | 24 | $284 | $12 |
| Ondansetron | 31 | $244 | $8 |
| Gabapentin | 28 | $219 | $8 |
| Omeprazole | 28 | $198 | $7 |
| Diphenoxylate-Atropine | 13 | $183 | $14 |
| Dexamethasone | 24 | $174 | $7 |
| Lorazepam | 17 | $126 | $7 |
| Letrozole | 13 | $73 | $6 |
| Prochlorperazine Maleate | 13 | $70 | $5 |
2016: 10 drugs
| Gleevec | 11 | $111,389 | $10,126 |
| Xarelto | 22 | $7,206 | $328 |
| Enoxaparin | 12 | $5,321 | $443 |
| Anastrozole | 75 | $887 | $12 |
| Tamoxifen Citrate | 19 | $586 | $31 |
| Hydroxyurea | 11 | $278 | $25 |
| Gabapentin | 17 | $190 | $11 |
| Ondansetron | 14 | $185 | $13 |
| Letrozole | 13 | $159 | $12 |
| Dexamethasone | 14 | $50 | $4 |
2015: 1 drug
| Acyclovir | 11 | $137 | $12 |
Money from drug and device companies
$224 in 2025
| 2025 | 2 | 2 | None | $224 |
| 2024 | 2 | 3 | None | $161 |
| 2023 | 5 | 6 | None | $714 |
| 2022 | 5 | 9 | None | $603 |
| 2021 | 7 | 9 | None | $519 |
| 2020 | 4 | 5 | None | $147 |
| 2019 | 6 | 14 | None | $1,070 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Bayer Healthcare Pharmaceuticals | Kerendia | $118 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $106 | 1 payment
|
See all 2 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-12 | Lynparza | $106 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-22 | Kerendia | $118 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $161
| Bayer Healthcare Pharmaceuticals | Nubeqa | $122 | 1 payment
|
| Mannkind | Afrezza | $39 | 2 payments
|
2023: $714
| Sirtex Medical | Sir-Spheres Microspheres | $267 | 1 payment
|
| ADC Therapeutics America | None | $168 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $97 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $93 | 1 payment
|
| MannKind | Afrezza | $90 | 1 payment
|
2022: $603
| Biotronik | Solia | $247 | 2 payments
|
| Abbott Laboratories | Cardiomems | $162 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $87 | 1 payment
|
| Mannkind | Afrezza | $83 | 4 payments
|
| Eisai | Lenvima | $25 | 1 payment
|
2021: $519
| Abbott Laboratories | Fortify Assura, Ellipse Icd | $190 | 1 payment
|
| Genzyme | Jevtana | $122 | 1 payment
|
| Biotronik | Solia | $112 | 1 payment
|
| MannKind | Afrezza | $57 | 3 payments
|
| Acrotech Biopharma | Beleodaq | $14 | 1 payment
|
| Lilly USA | Taltz | $12 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $147
| Philips Electronics North America | (7999) Src Undivided | $87 | 1 payment
|
| Eisai | Lenvima | $26 | 2 payments
|
| EMD Serono | Bavencio | $21 | 1 payment
|
| Pfizer | Xtandi | $14 | 1 payment
|
2019: $1,070
| Biotronik | None | $485 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $248 | 2 payments
|
| Pfizer | Xtandi | $125 | 1 payment
|
| Astellas Pharma US | Xtandi | $123 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $64 | 3 payments
|
| Rigel Pharmaceuticals | Tavalisse | $26 | 1 payment
|
Professional record
- NPI
- 1487807111
- Licence
- CA A112936California A112936: Current · expires 2027-08-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X)
- Mailing address
- 2589 Samaritan Dr, San Jose, CA, 95124
- NPI first listed
- 2008-10-26
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305